Dynamk Capital
New York · Seed–Series B
What they invest in
from 2 of 21 portfolio companiesBiotech ×2Medical Devices ×2AI & Machine Learning ×1Deep Tech ×1Healthtech ×1
HQs:United Kingdom×1United States×1
Investments · 21 tracked
founders shown can be your intro pathFull-stack solution for non-destructive 3D imaging of large tissues at sub-cellular resolution using proprietary chemistry, high-throughput light-sheet microscopy, and cloud-based AI analysis.
Develops analytical testing devices that minimize sample volume requirements for particle count determination in biopharmaceutical analysis.
bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications. The company markets cells and disease models through its ioCells brand for use in biomedical research and therapeutic development.
BiotechDeep TechHealthtechMedical Devices
Dr Mark Kotter(Founder)Przemek Obloj(CEO)
Enables next-generation cell and gene therapies by efficiently delivering gene-editing payloads while preserving cell function and viability.
Preclinical discovery platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and AI/ML-enabled phenotypic screening to accelerate drug discovery.
Envisagenics uses AI-driven analysis of RNA splicing to discover novel drug targets for immuno-oncology and neurodegenerative diseases. The company combines RNA biology expertise with machine learning to advance precision medicines.
AI & Machine LearningBiotechMedical DevicesNew York, US
Maria Pineda, PhD(CEO & Co-founder)Martin Akerman, PhD(CEO & Co-founder)
Uses RNA splicing analytics and artificial intelligence to reduce complexity of biomedical data and accelerate therapeutic solution development.
Manufactures handheld cell culture monitors that measure oxygen consumption in multi-well plates for continuous real-time cell analysis.
Simplifies human mesenchymal stem and stromal cell biomanufacturing and supplies critical reagents to advance regenerative medicine.
A stem cell tools and technology company providing standardized platforms to accelerate regenerative medicine development and clinical trials.
Provides high-purity mRNA and LNP-mRNA manufacturing services for applications ranging from drug discovery to clinical development.
Develops the Viral Sensitizer platform to reduce production inefficiencies in manufacturing of viral-based therapies, cell therapies, and vaccine candidates.
Designs hardware and AI-driven software platforms for drug screening, primary cell analysis, and cell therapy manufacturing to enhance safety and performance.
Frequently asked questions
- What stage does Dynamk Capital invest at?
- Dynamk Capital invests at the Seed, Series A, Series B stages.
- Where is Dynamk Capital located?
- Dynamk Capital is headquartered in New York, US.
Similar investors
500 Global's Sustainable Growth practice designs and implements sovereign-aligned strategies that unlock resilient, inclusive, and sustainable economic growth across the Global Majority—Asia, Africa, Latin America, and the Middle East. The practice bridges public priorities and private capital through ecosystem development, blended finance, and localized innovation programs addressing health, agriculture, gender, climate, and education.
a16z is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz that invests in seed through growth-stage technology companies across multiple sectors including AI, healthcare, consumer, crypto, enterprise, fintech, and gaming. The firm manages over $100 billion in assets and operates a distinctive platform model with a large team of operators supporting founders throughout their journey.
August Capital is a venture capital firm headquartered in the San Francisco Bay Area that has invested in early-stage startups across information technology since 1995. The firm manages approximately $2 billion in assets and combines capital deployment with operational support and networking assistance to help entrepreneurs build successful companies.